TY - JOUR
T1 - Impact of childhood maltreatment on outcomes of antidepressant medication in chronic and/or recurrent depression
AU - Medeiros, Gustavo C.
AU - Prueitt, William L.
AU - Rush, A. John
AU - Minhajuddin, Abu
AU - Czysz, Andrew H.
AU - Patel, Shirali S.
AU - Trombello, Joseph
AU - Trivedi, Madhukar H.
N1 - Funding Information:
Dr. Rush has received consulting fees from Akili, Brain Resource Inc., Compass Inc., Curbstone Consultant LLC., Emmes Corp, Holmusk, Inc., Johnson and Johnson, Liva-Nova, Sunovion, USA, Taj Medical; speaking fees from Liva-Nova; royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX. (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7795033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS and U.S. Patent No. 7906283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. Dr. Trivedi has provided consulting services to Acadia Pharmaceuticals, Inc., Allergan, Inc., Alto Neuroscience Inc, Axsome Therapeutics, Engage Health Media, GreenLight VitalSign6 Inc, Janssen, Merck Sharp & Dohme Corp., Myriad Neuroscience, Navitor Pharmaceutical Inc, Otsuka, Perception Neuroscience, SAGE Therapeutics, and Signant Health. He has received grant/resesrch funding from NIMH, NIDA, Patient-Centered Outcomes Research Institute (PCORI), and Cancer Prevention Research Institute of Texas (CPRIT). Additionally, he has received editorial compensation from Oxford University Press. Drs. Medeiros, Prueitt, Minhajuddin, Patel, Czysz, Patel and Trombello have no conflicts to report.
Funding Information:
The CO-MED trial (NCT00590863) was funded by NIMH (N01 MH-90003, Trivedi MH and Rush AJ PIs), and in part by the Hersh Foundation (Trivedi MH PI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Forest Pharmaceuticals, GlaxoSmithKline, Organon, and Wyeth Pharmaceuticals provided medications for this trial at no cost. Research reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R25MH101078 (Trivedi MH PI).
Publisher Copyright:
© 2021
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Background: While childhood maltreatment (CMT) is associated with higher rates of chronicity and recurrence in depression, whether CMT results in poorer outcomes with antidepressant medication remains unclear. Methods: We performed secondary analyses with data from the large, representative, multisite trial Combining Medications to Enhance Depression Outcomes (CO-MED). CO-MED was a randomized, single-blinded, placebo-controlled study with 665 individuals (663 assessed for CMT) with chronic and/or recurrent Major Depressive Disorder (MDD). CMT was determined by a brief self-reported questionnaire assessing the four types of CMT defined by the Centers for Disease Control and Prevention: sexual abuse, emotional abuse, physical abuse, and neglect. Repeated measures and logistic regression analyses were used. Results: Individuals with CMT did not have a differential improvement of depressive symptoms when compared to those without CMT (adjusted p=.203 for continuous analysis; adjusted p=.320 for remission rates). Neither type of antidepressant medication (adjusted p=.302) nor the age at which CMT occurred (adjusted p=.509) affected depressive symptom outcomes. There was no difference in functional improvement between individuals with and without CMT (adjusted p=.228). A history of CMT was associated with greater antidepressant side effects (p=.009). Limitations: This study investigated treatment-seeking individuals with chronic and/or recurrent MDD. Intensity and duration of CMT were not assessed. Conclusion: In a sample of treatment-seeking outpatients with chronic and/or recurrent MDD, a history of CMT was not associated with differential symptomatic or functional response to pharmacological treatment. However, those with CMT reported greater antidepressant side effect burden.
AB - Background: While childhood maltreatment (CMT) is associated with higher rates of chronicity and recurrence in depression, whether CMT results in poorer outcomes with antidepressant medication remains unclear. Methods: We performed secondary analyses with data from the large, representative, multisite trial Combining Medications to Enhance Depression Outcomes (CO-MED). CO-MED was a randomized, single-blinded, placebo-controlled study with 665 individuals (663 assessed for CMT) with chronic and/or recurrent Major Depressive Disorder (MDD). CMT was determined by a brief self-reported questionnaire assessing the four types of CMT defined by the Centers for Disease Control and Prevention: sexual abuse, emotional abuse, physical abuse, and neglect. Repeated measures and logistic regression analyses were used. Results: Individuals with CMT did not have a differential improvement of depressive symptoms when compared to those without CMT (adjusted p=.203 for continuous analysis; adjusted p=.320 for remission rates). Neither type of antidepressant medication (adjusted p=.302) nor the age at which CMT occurred (adjusted p=.509) affected depressive symptom outcomes. There was no difference in functional improvement between individuals with and without CMT (adjusted p=.228). A history of CMT was associated with greater antidepressant side effects (p=.009). Limitations: This study investigated treatment-seeking individuals with chronic and/or recurrent MDD. Intensity and duration of CMT were not assessed. Conclusion: In a sample of treatment-seeking outpatients with chronic and/or recurrent MDD, a history of CMT was not associated with differential symptomatic or functional response to pharmacological treatment. However, those with CMT reported greater antidepressant side effect burden.
UR - http://www.scopus.com/inward/record.url?scp=85107284834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107284834&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2021.04.022
DO - 10.1016/j.jad.2021.04.022
M3 - Article
C2 - 34023746
AN - SCOPUS:85107284834
SN - 0165-0327
VL - 291
SP - 39
EP - 45
JO - Journal of affective disorders
JF - Journal of affective disorders
ER -